Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nipro to Set Up Pharmaceutical Plant in Vietnam for Contract Manufacturing of Generics
January 11, 2012
- Interprotein, Takeda to Collaborate on Molecular Designing of PPI Modulators
January 11, 2012
- Observation Period Ended in PII/III Trial of Elpamotide: OncoTherapy
January 11, 2012
- DWTI’s Antiplatelet Agent Enters Late PII Stage
January 11, 2012
- Bayer Submits Rivaroxaban in EU, US for Add’l Indication
January 11, 2012
- Top Managements of Pharmaceutical Companies Express Complaints for Additional Price Cut for Long-Listed Drugs
January 10, 2012
- Bayer Yakuhin to Promote Long-Listed Products Without Mediation by MRs
January 10, 2012
- Bayer Yakuhin President Guth Says Marketing Success of 2 Strategic Products Key Focus
January 10, 2012
- Toho HD Chairman Matsutani Showed Enthusiasm for 3rd Round of Distribution Improvement Talks
January 10, 2012
- Takeda and Osaka Univ. Establish Joint Research Chair for Nano-particle Vaccines
January 10, 2012
- Astellas Terminates License Agreement for VIBATIV Injection
January 10, 2012
- Asahi Kasei Pharma Launches Flivas in South Korea through Dong-A
January 10, 2012
- Pharmacist Survey Shows Meiji Seika Pharma Rise to 3rd Rank for “Memorable” MRs
January 6, 2012
- Deutsche Securities Report Says Patent Cliff Concerns Scarce for MTPC
January 6, 2012
- AZ President Hudson Says Development of Japanese Leaders One of Key Company Issues
January 6, 2012
- AZ to Utilize E-detailing, Optimize According to Product
January 6, 2012
- Top Execs Stress Importance of Emerging Markets, Compliance in New Year's Addresses
January 6, 2012
- Toray to Take Equity Stake in Mitsui’s Subsidiary
January 6, 2012
- Seikagaku Changes Sales Partner for Supartz in US
January 6, 2012
- Astellas Directed to Suspend Export of Gaster to South Korea Due to Use of Unapproved API
January 6, 2012
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…